RETOFRAXGENE PARVEC
UNII AP4CW4W3BP

Substance Identification & Data

This profile provides standardized clinical and technical data for Retofraxgene Parvec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) AP4CW4W3BP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3062583-58-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

AP4CW4W3BP

CAS Registry Number

3062583-58-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RETOFRAXGENE PARVEC

Official standardized name for this substance within the FDA UNII nomenclature system.

INN ID

13984

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Retofraxgene Parvec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RETOFRAXGENE PARVEC

Common Names & Synonyms

RECOMBINANT NON-REPLICATING ADENO-ASSOCIATED VIRUS SEROTYPE RHESUS 10 (RAAVRH.10) VECTOR ENCODING THE FULL-LENGTH HUMAN FRATAXIN (FXN) PRECURSOR PROTEIN PRECEDED BY A KOZAK SEQUENCE. TRANSGENE EXPRESSION IS UNDER CONTROL OF THE SYNTHETIC CAG PROMOTER (HUMAN CYTOMEGALOVIRUS ENHANCER, CHICKEN .BETA.-ACTIN PROMOTER, RABBIT .BETA.-GLOBIN INTRON) AND TERMINATED WITH A RABBIT .BETA.-GLOBIN POLYADENYLATION SIGNAL; FLANKED BY AAV2 INVERTED TERMINAL REPEATS (ITRS)

RETOFRAXGENE PARVEC [INN]

External Clinical & Regulatory Resources

Previous UNIIAP46ZUQ945

Next UNIIAP4OF2M98B